10-K: Cara Therapeutics Explores Strategic Alternatives, Merger with Tvardi Therapeutics Proposed

Cara Therapeutics is exploring strategic alternatives, including a proposed merger with Tvardi Therapeutics, after discontinuing its clinical program in notalgia paresthetica.

Summary

• Cara Therapeutics is exploring strategic alternatives focused on maximizing shareholder value, including a proposed merger with Tvardi Therapeutics.
• The decision follows the discontinuation of the clinical program in notalgia paresthetica (NP) after oral difelikefalin did not demonstrate a meaningful clinical benefit in the KOURAGE-1 study.
• Cara has entered into a merger agreement with Tvardi, subject to stockholder approval and other customary closing conditions.
• As a condition of the merger, Tvardi must have received satisfactory evidence that the Asset Disposition will be consummated substantially concurrently with the closing of the Merger.
• If the merger is completed, the business of Tvardi will continue as the business of the combined company.
• Cara has also entered into an Asset Purchase Agreement (APA) with CSL Vifor to sell certain assets and rights related to difelikefalin for $900,000, subject to adjustments.
• The Asset Disposition is subject to certain conditions to closing, including either (i) the consummation of the Merger concurrently with the Asset Disposition or (ii) the receipt of the requisite stockholder approval needed to approve the Asset Disposition in the event that the Merger is terminated.
• Cara's future operations are highly dependent on the success of the Merger and the Asset Disposition.
• In December 2024, Cara effected a one-for-twelve (12) reverse stock split.
• KORSUVA injection net sales in the United States were approximately $2.1 million in 2024, $26.5 million in 2023 and $35.0 million in 2022.
• Cara recorded collaborative revenue of $2.1 million, $12.4 million and $16.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.
• Cara expects no meaningful revenue contribution from KORSUVA injection following the TDAPA period expiration.
• Cara recorded royalty revenue of approximately $415,000 and $72,000 for the years ended December 31, 2023 and 2022, respectively.
• Cara recorded other revenue of approximately $4.3 million for the year ended December 31, 2024, of which approximately $1.5 million related to CSL Vifor royalties to be paid to HCR under this agreement and approximately $2.8 million related to Maruishi royalties to be paid to HCR under this agreement.
• Cara had federal and state NOL carryforwards of approximately $475.4 million and $403.1 million, respectively, and Cara also had federal and state R&D tax credit carryforwards of approximately $28.6 million and $4.4 million, respectively, as of December 31, 2024.
• Cara incurred net losses of $70.9 million, $118.5 million and $85.5 million for the years ended December 31, 2024, 2023 and 2022, respectively.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's a potential merger, the company faces financial challenges and discontinued programs, leading to a slightly negative outlook.

Positives

• The proposed merger with Tvardi Therapeutics could provide a new strategic direction for the company.
• The Asset Disposition with CSL Vifor will allow Cara to focus on other strategic alternatives.
• The company has significant NOL and R&D tax credit carryforwards.

Negatives

• The clinical program in notalgia paresthetica (NP) was discontinued after oral difelikefalin did not demonstrate a meaningful clinical benefit.
• KORSUVA injection net sales in the United States have decreased significantly.
• Cara expects no meaningful revenue contribution from KORSUVA injection following the TDAPA period expiration.
• Cara has incurred significant net losses and negative cash flows from operating activities.
• Cara may decide to pursue a dissolution and liquidation of Cara if the Merger is not successful.

Risks

• Failure to complete the merger with Tvardi could materially and adversely affect Cara's results of operations, business, financial results and/or stock price.
• Cara may not be successful in completing the Merger, and any strategic transactions that it may consummate in the future could have negative consequences.
• If Cara does not successfully consummate the Merger or another strategic transaction, Caras Board may decide to pursue a dissolution and liquidation of Cara.
• Cara is substantially dependent on its remaining employees to facilitate the consummation of the Merger.
• Cara may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
• If Cara fails to regain and maintain compliance with the continued listing standards of the Nasdaq Capital Market, Cara may be delisted and the price of its common stock, its ability to access the capital markets and its financial condition could be negatively impacted.

Future Outlook

Cara expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund its currently anticipated operating plan for at least the next 12 months.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Cara faces potential competition from many different sources, including large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, and medical technology companies.

Comparison to Industry Standards

• The document does not contain specific details listing specific comparable companies, projects, and results.
• Therefore, a comparison to industry standards cannot be made.

Corporate Governance

Related Party Transactions

• CSL Vifor, a related party due to stock ownership, is a key partner for KORSUVA injection commercialization.
• Cara has entered into a license agreement with CKDP, a related party, for the development, manufacture and commercialization of drug products containing difelikefalin in South Korea.

Stakeholder Impact

• Shareholders face uncertainty regarding the success of the merger and potential liquidation.
• Employees have been impacted by workforce reductions.
• Customers (patients) may experience changes in access to KORSUVA injection due to commercialization changes.
• Suppliers and creditors may be affected by the company's financial situation and strategic decisions.

Next Steps

• Obtain stockholder approval for the merger with Tvardi Therapeutics.
• Satisfy other customary closing conditions for the merger.
• Complete the Asset Disposition with CSL Vifor.
• Potentially explore other strategic alternatives if the merger is not consummated.

Key Dates